Today is Tuesday, Mar. 26, 2019

Department of

Cancer Biology

Jensen Mini-Symp 2018 Sitefinity Web Banner

Keynote Speakers:

 Bert W. O'Malley, M.D. Bert W. O'Malley, M.D.
    Chancellor of Baylor College of Medicine 
    Thompson Professor of Molecular and Cellular Biology
    (NAS, NAM Member and National Medal of Science Winner)

    Dr. Bert O'Malley is the Tom Thompson Distinguished Leadership and Service Professor of Molecular and Cellular Biology and Chancellor at Baylor College of Medicine. He graduated medical school at U. Pittsburgh, followed by periods at Duke, NIH, and Vanderbilt. He was first to discover that nuclear receptors are transcription factors that regulate mRNA production in target cells in response to intracellular hormones. He uncovered mechanisms for activating steroid receptors, and discovered the existence of 'coregulators', the coactivators and corepressors of gene transcription. The coregulators turned out to be the long sought 'master regulators' of mammalian gene function. His work led to a molecular understanding of how hormonal antagonists work and had major importance to reproduction, genetic disease, metabolism, and especially cancers. Dr. O'Malley is the founding father of the field of Molecular Endocrinology and a member of the National Academy of Sciences and the National Academy of Medicine, and has received over 60 honors and awards for his work, including the National Medal of Science (White House, 2008). He has trained over 250 scientists and published over 700 papers and holds 26 patents in the fields of Gene Regulation, Molecular Endocrinology and Steroid Receptor and Coactivator Action. He developed a later interest in the impressive cooperation of nuclear proteins in dysfunctional processes of transcription in cancer, metabolic disease, and heart damage. This interest was fueled by his recent many studies of the entire coregulatsome of mammals detailing the crossover roles of transcription/repair coactivator proteins. In very recent work, he developed the concept that small molecules can regulate coactivators to produce therapeutic outcomes for diseases such as cancer.
 W. Lee Kraus, PhD W. Lee Kraus, Ph.D.
Cecil H. and Ida Green Distinguished Chair in Reproductive Biology Sciences
    Director of the Cecil H. and Ida Green Center for Reproductive Biology Sciences
    UT Southwestern Medical Center

    Dr. W. Lee Kraus is the Director of the Cecil H. and Ida Green Center for Reproductive Biology Sciences at University of Texas South Western Medical Center.  He is also Professor and Vice Chair for Basic Sciences in the Department of Obstetrics and Gynecology, and Professor of Pharmacology.   Dr. Kraus received his Ph.D. in 1994 from the University of Illinois, Urbana-Champaign, where he studied gene regulation by steroid hormone signaling pathways.  He completed his postdoctoral work at UC San Diego in 1998, where he studied the mechanisms of estrogen-regulated transcription from chromatin.   Dr. Kraus was on the faculty at Cornell University in Ithaca, NY from 1999 to 2010, rising through the ranks to full professor.  Since July 2010, he has been at UT Southwestern.  He is also a founder of Ribon Therapeutics, Inc., a biopharmaceuticals startup focused on PARP monoenzymes, which began operations in 2015.
    Dr. Kraus’ research has led to new information about the connections between hormone-regulated gene expression and the gene-regulating effects of chromatin, which has implications for understanding and treating breast cancers.  His recent work has helped to characterize the estrogen-regulated transcriptome and identify thousands of novel non-coding RNAs.  It has also led to some surprising new conclusions about the activity of poly(ADP-ribose) polymerase-1 (PARP-1), an NAD+-regulated nuclear factor that connects cellular NAD+ levels to nuclear signaling, chromatin structure, and gene expression. 
    Dr. Kraus has served as an editor for Molecular Endocrinology and Molecular Cancer Research.  He is the founding organizer of the Cold Spring Harbor Laboratory meeting on the PARP family and has been an organizer of two Keystone Conferences on nuclear receptors.  He has been recognized for his outstanding research by the Endocrine Society with the Richard E. Weitzman Memorial Award for research excellence is 2007 and the Ernst Oppenheimer Award for research excellence in 2014.  Dr. Kraus holds the Cecil H. and Ida Green Distinguished Chair in Reproductive Biology Sciences at UT Southwestern Medical Center.
 Carol A. Lange, Ph.D. Carol A. Lange, Ph.D.
    Professor of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology
    Tickle Family Land Grant Endowed Chair 
    Co-Lead, Cellular Mechanisms Program
    University of Minnesota Masonic Cancer Center

    Carol A. Lange, Ph.D. is the Tickle Family Land Grant Endowed Chair of Breast Cancer Research and Professor of Medicine and Pharmacology at the University of Minnesota Masonic Cancer Center (MCC) in Minneapolis, Minnesota, where she serves as Director of the Cancer Biology Training (NIH/NCI T32) Program and Co-Leader of the Cellular Mechanisms of Cancer Program within the MCC. Her research is focused on steroid hormone receptor action and signal transduction in breast and ovarian cancer. Her lab studies mechanisms of gene regulation by cross talk between growth factor-mediated signaling pathways and steroid hormone receptors, using the human progesterone receptor (PR) as an understudied model receptor that is highly relevant to ER+ women's cancer and stem cell biology. Additional research focus is aimed at targeting stress-activated signaling pathways (p38 MAPKs, ERK5, HIFs, cortisol and glucocorticoid receptors (GR)) as inputs to GR-target gene expression in breast cancer progression. A key phospho-GR target gene discovered in the Lange lab, known as breast tumor kinase (Brk/PTK6), drives advanced breast and ovarian cancer phenotypes (invasion, metastasis, changes in cancer stem cell biology).  Dr. Lange has served on numerous NIH and DOD study sections. She is Editor-in-Chief of the journal Hormones and Cancer (Springer/Nature) and a Scientific Advisor to the NIEHS.
 C. Kent Osborne, M.D. C. Kent Osborne, M.D. 
    Director, Dan L Duncan Comprehensive Cancer Center
    Tina and Dudley Sharp Chair in Oncology
    Professor of Medicine and Molecular and Cellular Biology
    Baylor College of Medicine

    Dr. C. Kent Osborne was born in 1946 in St. Louis, Missouri. He received his AB and MD degrees from the University of Missouri, both with honors. He completed his internship and residency at Johns Hopkins Hospital in 1974, and then spent three years as a clinical associate at the Medicine Branch, Breast Cancer Section of the National Cancer Institute in Bethesda, Maryland. In 1977, he took his first faculty position at The University of Texas Health Science Center at San Antonio, where he rose to the rank of Professor and became Director of the Division of Medical Oncology in 1992. In 1999, Dr. Osborne and his team moved to Baylor College of Medicine to develop a new multidisciplinary Breast Center and in 2005 he was named Director of the new Dan L Duncan Cancer Center at Baylor College of Medicine which achieved “comprehensive” designation under his leadership in 2015.
    Dr. Osborne is a physician scientist who has focused on breast cancer his entire career. His research interests include understanding the biology of breast cancer and then developing new treatment approaches for the disease. He has published extensively on the mechanisms by which hormonal therapies such as tamoxifen inhibit breast cancer growth and how breast cancers become resistant to these therapies. He has also studied the role of various growth factors in breast cancer development and progression, and more recently how these other growth factors can interact with estrogen to stimulate tumor growth. His laboratory is also focusing on the mechanisms by which breast cancers develop resistance to HER2-targeted therapies. For more than a decade Dr. Osborne was Chairman of the Breast Cancer Committee for the Southwest Oncology Group, where he directed numerous nationwide clinical trials investigating new treatment strategies for breast cancer patients. He is currently the Principal Investigator of the Baylor Breast Cancer Specialized Program of Research Excellence grant which has been funded since the Program began in 1992.
    Dr. Osborne has received many awards for his accomplishments.  Among his awards are the Komen Foundation Award, the Brinker International Award for Breast Cancer Research, the European Institute of Oncology Annual Breast Cancer Award, the ASCO Bonadonna Award for Breast Cancer Research, The William L. McGuire Memorial Lectureship from the SABCS Symposium and most recently, The 2018 AACR Distinguished Investigator Award for Extraordinary Scientific Achievement and Leadership in Breast Cancer Research.  At Baylor College of Medicine, he is currently the Director of the Dan L Duncan Comprehensive Cancer Center and Professor of Medicine and Molecular and Cellular Biology and holds the Tina and Dudley Sharp Chair in Oncology at Baylor College of Medicine.

For further information contact Emily Spinks at 513.558.7379 or email

Hosted by University of Cincinnati Department of Cancer Biology and Division of Hematology/Oncology

Supported by

Jensen Symp 2018 e-Poster BRANDED

Cancer Biology Researcher

More Information:

Jensen Symposium
University of Cincinnati
College of Medicine Campus

Contact information:                       Emily Spinks                     513.558.7379                     

A complete copy of the 2018 Jensen Symposium booklet can be found at Jensen Symposium 2018 Abstract Booklet